Intergenerational living emphasizes socialization and cooperation across generations. This mixed methods study describes a novel intergenerational community in a personal care home that situates graduate health science students as neighbors to older adult residents. The study aims to assess student attitudes about aging and the impact on quality of life from both student and older adult resident perspectives. Quantitative student outcomes were assessed at the start/end of the academic year using the Relating to Older People Evaluation and the Geriatric Attitudes Scale. Qualitative reporting included interviews with student residents at the start/end and older adult residents at the end of that academic year. Quantitative results demonstrated no significant changes over time. Qualitative results include the value of intergenerational living, impacts on mental health through relationships, and learning from wisdom. Intergenerational living communities could possibly improve the quality of life of both students and older adults.
This methodological paper adds to the growing empirical research on pl & aacute;tica as methodology and method through a critical lens when researching with Latine populations, thus cultivating equitable educational and research systems for the 21st century. Using our dissertation studies as examples, which focus on AfroLatine/a/o activists and queer and trans-Latine students, we demonstrate how using pl & aacute;tica methodology and methods enables transformative ways to center and research Latine experiences.
The CLAS12 RICH detector installed in the Hall B of the Jefferson Laboratory has been designated to provide clean kaon identification in the momentum range from 3 to 8 GeV/c. The detector adopted a novel hybrid design, with aerogel radiator, a system of planar and spherical mirrors and a highly segmented readout system based on multi-anode photomultipliers. We present here the status of the detector and its performance after a few years of operation.
Across his clinical career, Frantz Fanon engaged with the theory and practice of institutional psychotherapy (also called social therapy). Social therapy aimed not only to treat individual patients' psychic suffering but also to critically interrogate and intervene upon the psychiatric asylum's isolating and hierarchical social organization. Later in his career, Fanon arrives at important critiques of social therapy. However, he never stopped implementing social therapy interventions as the director of psychiatric hospitals in Algeria and Tunisia, including the creation of hospital libraries, reading groups, and patient-run journals. In his own editorial contributions to these journals, Fanon discusses these kinds of collective reading and writing practices as privileged technologies that can be engaged toward both individual and collective disalienation. Upon contextualizing Fanon's various uses and critiques of social therapy, this article focuses on how Fanon's editorials in hospital journals posit reading and writing as "higher acts." Within these editorials, Fanon illuminates how reading and writing practices are uniquely endowed with the ability to disrupt the isolated and isolating nature of inpatient psychiatric care.
Introduction:We conducted an etiology-stratified network meta-analysis of first-line systemic therapies for advanced HCC to compare newer regimens beyond sorafenib-based RCT evidence (HBV, HCV, or non-viral). Methods:Following PRISMA-NMA, we searched PubMed, Embase, Cochrane Library, and Web of Science to 01 June 2025 for first-line RCTs in advanced/unresectable HCC. Primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints were objective response rate (ORR) and grade ≥3 adverse events (AEs≥3). A Bayesian fixed-effects NMA (gemtc v4.4 with rjags) reported hazard ratios (HRs) or risk ratios (RRs) with 95% credible intervals, calculated SUCRA values for ranking, and assessed network coherence using deviance information criterion differences between consistency and inconsistency models. Protocol registered in PROSPERO (CRD420251074687). Results:Twenty-four RCTs (n=13,572) evaluating 26 first-line regimens formed a connected evidence network. In the overall population, regimens with significant OS advantage over sorafenib included sintilimab plus bevacizumab biosimilar (HR = 0.57, 95% CrI 0.43-0.75), camrelizumab plus rivoceranib (HR = 0.62, 0.48-0.79), and atezolizumab plus bevacizumab (HR = 0.66, 0.51-0.84). For PFS, top-ranked combinations were camrelizumab plus rivoceranib (HR = 0.52, 0.41-0.66), anlotinib plus penpulimab (HR = 0.53, 0.41-0.68), lenvatinib plus pembrolizumab (HR = 0.55, 0.44-0.68), and sintilimab plus bevacizumab biosimilar (HR = 0.56, 0.45-0.69). ORR was highest with lenvatinib plus pembrolizumab (RR = 8.00, 4.98-12.86). Regarding safety, tislelizumab (RR = 0.42, 0.33-0.52) and nivolumab (RR = 0.45, 0.36-0.56) were associated with the lowest incidence of AEs≥3. Etiology-stratified analyses indicated that, in HBV-related HCC, sintilimab plus bevacizumab biosimilar and atezolizumab plus bevacizumab led OS rankings, with PFS favoring cabozantinib plus atezolizumab and atezolizumab plus bevacizumab. In HCV-related HCC, only atezolizumab plus bevacizumab conferred a significant OS benefit (HR = 0.43, 0.25-0.73), while PFS superiority was observed only for cabozantinib plus atezolizumab (HR = 0.73, 0.54-0.99). In non-viral HCC, the STRIDE regimen (single priming dose tremelimumab plus durvalumab) was the only regimen to significantly improve OS (HR = 0.75, 0.59-0.96). Conclusions:For first-line therapy in advanced HCC, ICI-based combinations with anti-VEGF/anti-angiogenic agents generally outperform sorafenib, with discernible etiology-specific optima: HBV-related HCC favors sintilimab plus bevacizumab biosimilar or atezolizumab plus bevacizumab; HCV-related HCC favors atezolizumab plus bevacizumab; and in non-viral disease, STRIDE demonstrates a unique OS advantage. This etiology-stratified evidence framework may guide individualized first-line decision-making, pending confirmation in head-to-head trials. Systematic review registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251074687, CRD420251074687.
